For approval in the USA and Mexico, phase III of the clinical trial is expected to start in the coming weeks, Novavax announced on Monday in Gaithersburg (Maryland). So far, the company had expected the start by the end of November. Novavax claims to have received $ 1.6 billion through the US government’s vaccination program to expedite the delivery of a safe and effective vaccine. In Great Britain, around 15,000 participants have now been determined for phase III of the trial study there.
The Novavax share fell 4.5 percent before the IPO. In the meantime, the news also put a strain on the mood in the German leading index DAX, which then recovered. The US pharmaceutical company Moderna wants to apply for approval for its corona vaccine in the EU this Monday.
Novavax shares meanwhile gain 11.02 percent to 139.54 US dollars in NASDAQ trading.
/ men / ngu / jha /